IMMUNE RESPONSES TO HPVS INVOLVED IN GENITAL NEOPLASIA

人乳头瘤病毒(HPV)与良性和恶性有关 鳞状上皮增生性病变。宿主的免疫反应 HPV感染的特征不是很好，部分原因是HPV编码 作为抗原靶标的蛋白质很难获得。人乳头状瘤病毒感染 仅限于人类鳞状上皮细胞，通常不复制 到自然感染组织中的高密度。人乳头状瘤病毒还没有被 在组织培养细胞中成功繁殖，而人类是唯一 已知的动物宿主。作为HPV编码蛋白的替代来源 作为免疫反应的抗原，我们已经表达了dna。 克隆的HPV6b、HPV16和HPV16ORF的片段 大肠杆菌中的HPV18DNA是一种重组基因技术。这些 HPV类型特别令人感兴趣，因为它们与 女性生殖道独特的生物学疾病：HPV6b是最常见的 通常见于常见的生殖器尖锐湿疣(尖锐湿疣)和HPV16和 HPV18常与宫颈发育不良和 宫颈癌。人乳头瘤病毒编码蛋白将用于免疫学 检测以解决以下几个问题：1)确定哪些HPV蛋白 良性和恶性HPV诱导体液免疫和细胞免疫反应 女性生殖道疾病，2)以确定是否 对HPV6b、HPV16和HPV18蛋白的反应是特定类型的或 交叉反应，3)表征免疫的自然历史 在HPV相关疾病中的反应，以及40确定是否免疫 反应性是通过治疗干预来改变的。地址： 体液免疫表位和细胞免疫表位将通过核酸外切酶绘制 III-缺失融合蛋白构建体和人乳头瘤病毒衍生的合成肽。 这一信息可能对进一步描述两国关系有价值。 人类乳头状瘤病毒对生殖道良恶性疾病的影响 评估治疗干预措施的效果以及在发展HPV方面的作用 疫苗。

Human papillomaviruses (HPVs) are associated with benign and malignant proliferative lesions of squamous epithelium. The host immune response to HPV infections is not well characterized, in part because HPV-encoded proteins to serve as antigen targets are difficult to obtain. HPVs infect exclusively human squamous epithelial cells, and generally do not replicate to high densities in naturally infected tissues. HPVs have not been successfully propagated in tissue culture cells, and humans are the only known animal host. As an alternative source of HPV-encoded proteins to serve as antigen in assays of immune reactivity, we have expressed DNA fragments from the open reading frames (ORFs) of cloned HPV6b, HPV16, and HPV18 DNAs in Escherichia coli be recombinant genetic techniques. These HPV types are of particular interest because they are associated with biologically distinct diseases of the female genital tract: HPV6b is most often found in common genital warts (condylomata acuminata), and HPV16 and HPV18 are frequently associated with uterine cervical dysplasia and cervical carcinoma. The HPV-encoded proteins will be used in immunological assays to address several issues: 1) to identify those HPV proteins which induce humoral and cellular immune responses in benign and malignant HPV diseases of the female genital tract, 2) to determine whether the reactivities to HPV6b, HPV 16, and HPV18 proteins are type-specific or cross-reactive, 3) to characterize the natural history of the immune responses in HPV-related diseases, and 40 to determine whether immune reactivities are modified by therapeutic intervention. The locations of humoral and cellular immune epitopes will be mapped by using exonuclease III-deleted fusion protein constructs and HPV-derived synthetic peptides. This information may be valuable in further characterizing the relationship of HPVs to benign and malignant diseases of the genital tract, in evaluating the effects of therapeutic interventions, and in developing HPV vaccines.